BMY Stock Slumps 4% After It Scraps Heart Drug Study

• Bristol Myers said that it will halt the study of Milvexian in treating acute coronary syndrome. 
• The company will, however, continue its late-stage trials of the anticoagulant in patients with atrial fibrillation (AF) and for secondary stroke prevention (SSP).

Bristol Myers Squibb (BMY) announced on Friday that it has decided to halt its late-stage trial evaluating the efficacy and safety of Milvexian when added to conventional antiplatelet therapy in patients following a recent acute coronary syndrome (ACS) event.

Acute coronary syndrome (ACS) is an umbrella term for situations in which blood supplied to the heart muscle is suddenly reduced, usually due to a clot. It includes heart attack, and unstable angina, manifesting as sudden severe chest pain. According to Bristol Myers, more than seven million people in the world are diagnosed with ACS every year.

The decision follows an analysis by an independent data monitoring committee indicating that the trial is unlikely to meet its primary goal, the company stated. It further noted that no new safety concerns were identified with the investigational therapy, which is being developed in collaboration between Bristol Myers Squibb and Johnson & Johnson.

Which Trials Will Continue?

The company will, however, continue its late-stage trials of the anticoagulant in patients with atrial fibrillation (AF) and for secondary stroke prevention (SSP), it added. Data from the trials is expected in 2026.

“Our belief in both the SSP and AF studies remains high and is rooted in robust data from large Phase 2 clinical studies conducted in relevant patient populations and on different background treatments. The Librexia SSP and AF studies are distinct from Librexia ACS in several aspects, including patient populations, endpoints, type and duration of background therapy and disease pathology.” said Roland Chen, MD, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb.

How Did Stocktwits Users React?

Shares of the company traded 4% lower at the time of writing. On Stocktwits, retail sentiment around BMY stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.

BMY stock is down 17% this year and by 20% over the past 12 months. 

Also See: Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes

For updates and corrections, email newsroom[at]stocktwits[dot]com

Share

·

Add us on